FIGURE 5.

CEBPB targets FXR to affect the glycolysis of colon cancer and cell growth. (A) Protein level of CEBPB and FXR in each treatment group. (B–C) Seahorse XP96 was applied to analyze ECAR and OCR in cells in each treatment group. The glycolysis level and capability, basic oxygen consumption ratio, and the maximum oxygen consumption ratio were calculated based on the test results. (D) Contents of pyruvic acid, lactic acid, citric acid and malic acid were measured in cells in each treatment group. (E) Cell proliferation capability in each treatment group. (F) CCK‐8 was adopted to dig out cell proliferation viability in each treatment group. OD value was set at 450 nm, and the cell proliferation viability was measured at 0, 24, 48 and 72 h. (G) Cell apoptosis rate in each treatment group. Cell grouping setting of group A–G: Vector+oeNC, oeCEBPB+oeNC, oeCEBPB+oeFXR, Vector+siNC, siCEBPB+siNC, siCEBPB+siFXR. * p < 0.05